A systematic review including eight clinical trials and 9424 participants undergoing treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, with obesity but without diabetes resulted in a mean difference of −4.4 mmHg in SBP and a 7.1 kg decrease in body weight [23]. Here, GLP1R is linked to diabetes mellitus.